Sanofi SNY reported second-quarter 2025 adjusted earnings of 90 cents per American depositary share, which missed the Zacks ...

Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range Paris, July 31, 2025 Q2 sales growth of 10.1% at CER1 and business EPS2 ...

Experts see tolebrutinib as part of a broader shift toward treatments that target the neurodegeneration in MS, not just its ...

Fenebrutinib significantly reduced new lesions with active inflammation in people with relapsing MS in a Phase 2 trial.

Data about two brain-penetrant BTK inhibitors for MS -- fenebrutinib and tolebrutinib -- were presented at the 2025 American Academy of Neurology (AAN) annual meeting.

Sanofi (NASDAQ:SNY) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Berenberg Bank analyst Luisa Hector maintained a Buy rating on Sanofi (NASDAQ:SNY) on June 12, setting a ...

ALAIN JOCARD/AFP via Getty Images Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases.

Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib.

Sanofi SAN-0.13%decrease; red down pointing triangle agreed to buy Blueprint Medicines for up to $9.5 billion, the French drugmaker’s biggest move yet to replenish its drug pipeline since it ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an FDA-approved treatment.

Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on Dupixent. Read more about why SNY is still a Buy.

New research led by a St. Michael’s Hospital clinician-scientist and published in the prestigious New England Journal of Medicine suggests that a therapy called Tolebrutinib could reduce disability ...